Respiratory depression is the chief hazard from all opioid usage. Respiratory depression occurs most frequently in elderly or debilitated patients, usually following large initial doses in non-tolerant patients, or when opioids are given in conjunction with other agents that depress respiration. Common opioid side effects are constipation, nausea, sedation, dizziness, vomiting, headache, dry mouth, sweating, and weakness.

Oxycodone should be used with extreme caution in patients with significant chronic obstructive pulmonary disease and in patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression. In such patients, even usual therapeutic doses of oxycodone may decrease respiratory drive to the point of apnea. In these patients alternative non-opioid analgesics should be considered, and opioids should be employed only under careful medical supervision at the lowest effective dose.

Oxycodone causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic. Marked mydriasisrather than miosis may be seen due to hypoxia in overdose situations.

Gastrointestinal Tract and Other Smooth Muscle
Oxycodone causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in gastric, biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.

Cardiovascular System
Oxycodone may produce release of histamine with or without associated peripheral vasodilation. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.

Concentration--Efficacy Relationships (Pharmacodynamics)
Studies in normal volunteers and patients reveal predictable relationships between oxycodone dosage and plasma oxycodone concentrations, as well as between concentration and certain expected opioid effects. In normal volunteers these include pupillary constriction, sedation and overall "drug effect" and in patients, analgesia and feelings of "relaxation." In non-tolerant patients, analgesia is not usually seen at a plasma oxycodone concentration of less than 5&endash;10 ng/mL.

As with all opioids, the minimum effective plasma concentration for analgesia will vary widely among patients, especially among patients who have been previously treated with potent agonist opioids. As a result, patients need to be treated with individualized titration of dosage to the desired effect. The minimum effective analgesic concentration of oxycodone for any individual patient may increase with repeated dosing due to an increase in pain and/or the development of tolerance.

Summary of Medical Examiner Reports on Oxycodone-Related Deaths
Preface: The following is a summary of an ongoing study of medical examiner data regarding OxyContin® that is being conducted by the Drug Enforcement Administration (DEA).The DEA wrote letters to 775 medical examiners (MEs) from the National Association of Medical Examiners (NAME) requesting their reports (autopsy, toxicology, and ME investigative reports) on all deaths induced by, associated with, or related to oxycodone and/or, specifically, the oxycodone product, OxyContin® for 2000 and 2001. Based on the criteria described below, the reports received were categorized into four groups: 1) OxyContin® verified deaths; 2) OxyContin® likely deaths; 3) undetermined deaths; and 4) incomplete reports.
More...
New Rules Governing Internet Pharmacies Go Into Effect Next Week
APR 13 -- (Washington, DC)- New Drug Enforcement Administration (DEA) regulations implementing the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 go into effect Monday, April 13. These regulations will help to prevent the illegal diversion of powerful controlled substances by means of the Internet. Such medications can cause harm to consumers for whom they were not intended. The Interim Final Rule was published in the Federal Register this week, and the public has 60 days from its publication date to submit comments to the DEA.
More...
OxyContin is back in the news, and some would limit its availability...
September 9, 2003 First, for the News: There was a period of time when you couldn't watch a news broadcast or visit a news website without hearing or reading something about the issues associated with OxyContin®, it's abuse, and related issues. For many months, it seemed that all the controversy had died down. Actually, that wasn't the case, but it seemed to have lost it's charm in the media -- temporarily. Recently, it's back in the news, and the news is mixed for legitimate patients with chronic pain.
More...
The OxyContin 'Conspiracy' -- Is $700 Million Enough?
The OxyContin 'Conspiracy' -- Is $700 Million Enough? Some Experts Say Punishment Excessive, but Others Cite Gross Abuse of Medical System.Many doctors across the country are angry over what they consider an inadequate $700 million fine for the maker of OxyContin.
More...